Therapeutic implications of the tumor microenvironment in ovarian cancer patients receiving PD-1/PD-L1 therapy
Epithelial ovarian cancer (EOC) ranks as the second most common cause of gynecologic cancer death. The conventional treatment for patients with EOC is postoperative therapy along with platinum chemotherapy. However, a more efficient treatment regimen is of great need for these patients diagnosed wit...
Main Authors: | Yusha Wang, Lei Zhang, Yun Bai, Li Wang, Xuelei Ma |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2022-10-01
|
Series: | Frontiers in Immunology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2022.1036298/full |
Similar Items
-
Tumor Microenvironment in Hepatocellular Carcinoma: Key Players for Immunotherapy
by: Feng H, et al.
Published: (2022-10-01) -
Exercise sensitizes PD-1/PD-L1 immunotherapy as a hypoxia modulator in the tumor microenvironment of melanoma
by: Huiyu Yan, et al.
Published: (2023-10-01) -
Revisiting ovarian cancer microenvironment: a friend or a foe?
by: Boyi Zhang, et al.
Published: (2017-09-01) -
Clinical and Prognostic Value of Antigen-Presenting Cells with PD-L1/PD-L2 Expression in Ovarian Cancer Patients
by: Anna Pawłowska, et al.
Published: (2021-10-01) -
Immunomodulatory effects of regorafenib: Enhancing the efficacy of anti-PD-1/PD-L1 therapy
by: Junjie Liu, et al.
Published: (2022-09-01)